Company X T L Biopharmaceuticals Ltd Deutsche Boerse AG
Equities
US98386D2080
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
05/06 | XTL Biopharmaceuticals Signs Deal to Acquire The Social Proxy | MT |
05/06 | XTL Biopharmaceuticals Ltd. announced that it has received $1.5 million in funding | CI |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30/14/30 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 01/99/01 |
Doron Turgeman
CHM | Chairman | 56 | 30/14/30 |
Daphna Paran
CTO | Chief Tech/Sci/R&D Officer | - | 04/16/04 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30/14/30 |
Director/Board Member | 57 | 29/20/29 | |
Director/Board Member | 53 | 01/17/01 | |
Doron Turgeman
CHM | Chairman | 56 | 30/14/30 |
Director/Board Member | 46 | 08/14/08 | |
Director/Board Member | 57 | 01/15/01 | |
Director/Board Member | 63 | 08/14/08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 514,205,799 | 479,737,353 ( 93.30 %) | 0 | 93.30 % |
Company contact information
XTL Biopharmaceuticals Ltd.
26 Ben-Gurion Street
5112001, Ramat Gan
+972 3 611 6600
http://www.xtlbio.com![address X T L Biopharmaceuticals Ltd](https://cdn.zonebourse.com/static/address/11659063.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+25.83% | 47.96B | |
+45.66% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- XTLB Stock
- Stock
- Company X T L Biopharmaceuticals Ltd